Liu Jun, Wan Jing, Zhou Yi, Liu Zhong
Department of Otorhinolaryngology Head and Neck Surgery, Central Hospital of Enshi, Enshi, 445000, China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Jun;26(11):510-2.
To evaluate the efficacy and safety of subcutaneous immunotherapy with a standardized Dermatophagoides pteronyssinus extract for allergic rhinitis.
Sixty-eight patients with allergic rhinitis who received specific immunotherapy with a standardized dermatophagoides pteronyssinus extract were enrolled in this study. The clinical symptoms and signs were scored before and 2 years after treatment. Side effects were registered. Symptom and side effect scores were assessed to evaluate the clinical efficacy and safety.
There was a significant difference (P < 0.01) in symptom and medication scores between the two groups tow years after treatment. The patients had fewer symptoms and lower intake of medication. No severe systemic reactions were registered.
Immunotherapy with a standardized dermatophagoides pteronyssinus extract is effective and safe to treat patients clinically sensitive to this allergen.
评估标准化粉尘螨提取物皮下免疫疗法治疗变应性鼻炎的疗效和安全性。
本研究纳入68例接受标准化粉尘螨提取物特异性免疫疗法的变应性鼻炎患者。在治疗前和治疗2年后对临床症状和体征进行评分。记录不良反应。通过评估症状和不良反应评分来评价临床疗效和安全性。
治疗2年后两组之间症状和用药评分存在显著差异（P < 0.01）。患者症状减轻，药物摄入量降低。未记录到严重的全身反应。
标准化粉尘螨提取物免疫疗法对临床上对该变应原敏感的患者治疗有效且安全。
